WGSNasdaqServices-Health ServicesFiscal year ends December 31
GeneDx Holdings Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$66.29+2.68 (+4.21%)
Close on Oct 19, 2026
- Market cap
- $1.97B
- P/E (TTM)
- –
- Dividend yield
- –
GeneDx Holdings Corp. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 69.4%
- Operating margin
- -20.3%
- Net margin
- -23.4%
- Return on equity, FY2025
- -7.6%
Financial strength
- Current ratio
- 3.30
- Debt to equity
- 0.40
- Debt to assets
- 20.1%
- Cash to current liabilities
- 80.8%
Valuation
- P/E ratio
- –
- Price to sales
- 4.33
- Price to book
- 8.06
- Dividend yield
- –